UK markets closed
  • FTSE 100

    7,556.23
    -2.26 (-0.03%)
     
  • FTSE 250

    19,363.28
    -46.14 (-0.24%)
     
  • AIM

    853.32
    +2.76 (+0.32%)
     
  • GBP/EUR

    1.1656
    +0.0013 (+0.11%)
     
  • GBP/USD

    1.2296
    +0.0040 (+0.33%)
     
  • BTC-GBP

    13,845.35
    -12.20 (-0.09%)
     
  • CMC Crypto 200

    404.33
    +2.91 (+0.72%)
     
  • S&P 500

    4,071.70
    -4.87 (-0.12%)
     
  • DOW

    34,429.88
    +34.87 (+0.10%)
     
  • CRUDE OIL

    80.34
    -0.88 (-1.08%)
     
  • GOLD FUTURES

    1,811.40
    -3.80 (-0.21%)
     
  • NIKKEI 225

    27,777.90
    -448.18 (-1.59%)
     
  • HANG SENG

    18,675.35
    -61.09 (-0.33%)
     
  • DAX

    14,529.39
    +39.09 (+0.27%)
     
  • CAC 40

    6,742.25
    -11.72 (-0.17%)
     

Global Pulmonary / Respiratory Drug Delivery Market to Reach $66 Billion by 2027

ReportLinker
ReportLinker

Abstract: What’s New for 2022? Global competitiveness and key competitor percentage market shares. Market presence across multiple geographies - Strong/Active/Niche/Trivial.

New York, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Pulmonary / Respiratory Drug Delivery Industry" - https://www.reportlinker.com/p06361181/?utm_source=GNW
Online interactive peer-to-peer collaborative bespoke updates
Access to our digital archives and MarketGlass Research Platform
Complimentary updates for one year

Global Pulmonary / Respiratory Drug Delivery Market to Reach $66 Billion by 2027

In the changed post COVID-19 business landscape, the global market for Pulmonary / Respiratory Drug Delivery estimated at US$47.6 Billion in the year 2020, is projected to reach a revised size of US$66 Billion by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027. Metered Dose Inhalers, one of the segments analyzed in the report, is projected to record a 4.3% CAGR and reach US$28.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Dry Powder Inhalers segment is readjusted to a revised 5.5% CAGR for the next 7-year period.

The U.S. Market is Estimated at $13.8 Billion, While China is Forecast to Grow at 4.4% CAGR

The Pulmonary / Respiratory Drug Delivery market in the U.S. is estimated at US$13.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$11.6 Billion by the year 2027 trailing a CAGR of 4.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.1% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Nebulizers Segment to Record 4.7% CAGR

In the global Nebulizers segment, USA, Canada, Japan, China and Europe will drive the 4.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$9.8 Billion in the year 2020 will reach a projected size of US$13.7 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

Select Competitors (Total 42 Featured) -
AireHealth, LLC
Allergenix
Channel Products
Chemring Group PLC
Epalex Corp.
Genetic SpA
Micot
Omron Healthcare India
Pneuma Respiratory
Rotech Healthcare, Inc.


Read the full report: https://www.reportlinker.com/p06361181/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Pulmonary/ Respiratory Drug Delivery - Global Key Competitors
Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Asthma by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 2: World Historic Review for Asthma by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Asthma by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis for
Cystic Fibrosis by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for Cystic Fibrosis by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Cystic Fibrosis by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 8: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 10: World Pulmonary / Respiratory Drug Delivery Market
Analysis of Annual Sales in US$ Million for Years 2012 through
2027

Table 11: World Recent Past, Current & Future Analysis for
Pulmonary / Respiratory Drug Delivery by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 12: World Historic Review for Pulmonary / Respiratory
Drug Delivery by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 13: World 15-Year Perspective for Pulmonary / Respiratory
Drug Delivery by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World Markets for Years 2012, 2021 & 2027

Table 14: World Recent Past, Current & Future Analysis for
Metered Dose Inhalers by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 15: World Historic Review for Metered Dose Inhalers by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 16: World 15-Year Perspective for Metered Dose Inhalers
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 17: World Recent Past, Current & Future Analysis for Dry
Powder Inhalers by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 18: World Historic Review for Dry Powder Inhalers by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 19: World 15-Year Perspective for Dry Powder Inhalers by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 20: World Recent Past, Current & Future Analysis for
Nebulizers by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 21: World Historic Review for Nebulizers by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 22: World 15-Year Perspective for Nebulizers by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 23: World Recent Past, Current & Future Analysis for
Chronic Obstructive Pulmonary Disease (COPD) by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR

Table 24: World Historic Review for Chronic Obstructive
Pulmonary Disease (COPD) by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 25: World 15-Year Perspective for Chronic Obstructive
Pulmonary Disease (COPD) by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Pulmonary / Respiratory Drug Delivery Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in the United States
for 2022 (E)
Table 26: USA Recent Past, Current & Future Analysis for
Pulmonary / Respiratory Drug Delivery by Application - Asthma,
Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis
and Other Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 27: USA Historic Review for Pulmonary / Respiratory Drug
Delivery by Application - Asthma, Chronic Obstructive Pulmonary
Disease (COPD), Cystic Fibrosis and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 28: USA 15-Year Perspective for Pulmonary / Respiratory
Drug Delivery by Application - Percentage Breakdown of Value
Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD),
Cystic Fibrosis and Other Applications for the Years 2012, 2021 &
2027

Table 29: USA Recent Past, Current & Future Analysis for
Pulmonary / Respiratory Drug Delivery by Product - Metered Dose
Inhalers, Dry Powder Inhalers and Nebulizers - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 30: USA Historic Review for Pulmonary / Respiratory Drug
Delivery by Product - Metered Dose Inhalers, Dry Powder
Inhalers and Nebulizers Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 31: USA 15-Year Perspective for Pulmonary / Respiratory
Drug Delivery by Product - Percentage Breakdown of Value Sales
for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers
for the Years 2012, 2021 & 2027

CANADA
Table 32: Canada Recent Past, Current & Future Analysis for
Pulmonary / Respiratory Drug Delivery by Application - Asthma,
Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis
and Other Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 33: Canada Historic Review for Pulmonary / Respiratory
Drug Delivery by Application - Asthma, Chronic Obstructive
Pulmonary Disease (COPD), Cystic Fibrosis and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 34: Canada 15-Year Perspective for Pulmonary /
Respiratory Drug Delivery by Application - Percentage Breakdown
of Value Sales for Asthma, Chronic Obstructive Pulmonary
Disease (COPD), Cystic Fibrosis and Other Applications for the
Years 2012, 2021 & 2027

Table 35: Canada Recent Past, Current & Future Analysis for
Pulmonary / Respiratory Drug Delivery by Product - Metered Dose
Inhalers, Dry Powder Inhalers and Nebulizers - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 36: Canada Historic Review for Pulmonary / Respiratory
Drug Delivery by Product - Metered Dose Inhalers, Dry Powder
Inhalers and Nebulizers Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 37: Canada 15-Year Perspective for Pulmonary /
Respiratory Drug Delivery by Product - Percentage Breakdown of
Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and
Nebulizers for the Years 2012, 2021 & 2027

JAPAN
Pulmonary / Respiratory Drug Delivery Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
Table 38: Japan Recent Past, Current & Future Analysis for
Pulmonary / Respiratory Drug Delivery by Application - Asthma,
Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis
and Other Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 39: Japan Historic Review for Pulmonary / Respiratory
Drug Delivery by Application - Asthma, Chronic Obstructive
Pulmonary Disease (COPD), Cystic Fibrosis and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 40: Japan 15-Year Perspective for Pulmonary / Respiratory
Drug Delivery by Application - Percentage Breakdown of Value
Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD),
Cystic Fibrosis and Other Applications for the Years 2012, 2021 &
2027

Table 41: Japan Recent Past, Current & Future Analysis for
Pulmonary / Respiratory Drug Delivery by Product - Metered Dose
Inhalers, Dry Powder Inhalers and Nebulizers - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 42: Japan Historic Review for Pulmonary / Respiratory
Drug Delivery by Product - Metered Dose Inhalers, Dry Powder
Inhalers and Nebulizers Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 43: Japan 15-Year Perspective for Pulmonary / Respiratory
Drug Delivery by Product - Percentage Breakdown of Value Sales
for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers
for the Years 2012, 2021 & 2027

CHINA
Pulmonary / Respiratory Drug Delivery Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in China for 2022 (E)
Table 44: China Recent Past, Current & Future Analysis for
Pulmonary / Respiratory Drug Delivery by Application - Asthma,
Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis
and Other Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 45: China Historic Review for Pulmonary / Respiratory
Drug Delivery by Application - Asthma, Chronic Obstructive
Pulmonary Disease (COPD), Cystic Fibrosis and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 46: China 15-Year Perspective for Pulmonary / Respiratory
Drug Delivery by Application - Percentage Breakdown of Value
Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD),
Cystic Fibrosis and Other Applications for the Years 2012, 2021 &
2027

Table 47: China Recent Past, Current & Future Analysis for
Pulmonary / Respiratory Drug Delivery by Product - Metered Dose
Inhalers, Dry Powder Inhalers and Nebulizers - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 48: China Historic Review for Pulmonary / Respiratory
Drug Delivery by Product - Metered Dose Inhalers, Dry Powder
Inhalers and Nebulizers Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 49: China 15-Year Perspective for Pulmonary / Respiratory
Drug Delivery by Product - Percentage Breakdown of Value Sales
for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers
for the Years 2012, 2021 & 2027

EUROPE
Pulmonary / Respiratory Drug Delivery Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
Table 50: Europe Recent Past, Current & Future Analysis for
Pulmonary / Respiratory Drug Delivery by Application - Asthma,
Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis
and Other Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 51: Europe Historic Review for Pulmonary / Respiratory
Drug Delivery by Application - Asthma, Chronic Obstructive
Pulmonary Disease (COPD), Cystic Fibrosis and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 52: Europe 15-Year Perspective for Pulmonary /
Respiratory Drug Delivery by Application - Percentage Breakdown
of Value Sales for Asthma, Chronic Obstructive Pulmonary
Disease (COPD), Cystic Fibrosis and Other Applications for the
Years 2012, 2021 & 2027

Table 53: Europe Recent Past, Current & Future Analysis for
Pulmonary / Respiratory Drug Delivery by Geographic Region -
France, Germany, Italy, UK and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 54: Europe Historic Review for Pulmonary / Respiratory
Drug Delivery by Geographic Region - France, Germany, Italy, UK
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 55: Europe 15-Year Perspective for Pulmonary /
Respiratory Drug Delivery by Geographic Region - Percentage
Breakdown of Value Sales for France, Germany, Italy, UK and
Rest of Europe Markets for Years 2012, 2021 & 2027

Table 56: Europe Recent Past, Current & Future Analysis for
Pulmonary / Respiratory Drug Delivery by Product - Metered Dose
Inhalers, Dry Powder Inhalers and Nebulizers - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 57: Europe Historic Review for Pulmonary / Respiratory
Drug Delivery by Product - Metered Dose Inhalers, Dry Powder
Inhalers and Nebulizers Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 58: Europe 15-Year Perspective for Pulmonary /
Respiratory Drug Delivery by Product - Percentage Breakdown of
Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and
Nebulizers for the Years 2012, 2021 & 2027

FRANCE
Pulmonary / Respiratory Drug Delivery Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in France for 2022 (E)
Table 59: France Recent Past, Current & Future Analysis for
Pulmonary / Respiratory Drug Delivery by Application - Asthma,
Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis
and Other Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 60: France Historic Review for Pulmonary / Respiratory
Drug Delivery by Application - Asthma, Chronic Obstructive
Pulmonary Disease (COPD), Cystic Fibrosis and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 61: France 15-Year Perspective for Pulmonary /
Respiratory Drug Delivery by Application - Percentage Breakdown
of Value Sales for Asthma, Chronic Obstructive Pulmonary
Disease (COPD), Cystic Fibrosis and Other Applications for the
Years 2012, 2021 & 2027

Table 62: France Recent Past, Current & Future Analysis for
Pulmonary / Respiratory Drug Delivery by Product - Metered Dose
Inhalers, Dry Powder Inhalers and Nebulizers - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 63: France Historic Review for Pulmonary / Respiratory
Drug Delivery by Product - Metered Dose Inhalers, Dry Powder
Inhalers and Nebulizers Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 64: France 15-Year Perspective for Pulmonary /
Respiratory Drug Delivery by Product - Percentage Breakdown of
Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and
Nebulizers for the Years 2012, 2021 & 2027

GERMANY
Pulmonary / Respiratory Drug Delivery Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Germany for 2022:
( E)
Table 65: Germany Recent Past, Current & Future Analysis for
Pulmonary / Respiratory Drug Delivery by Application - Asthma,
Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis
and Other Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 66: Germany Historic Review for Pulmonary / Respiratory
Drug Delivery by Application - Asthma, Chronic Obstructive
Pulmonary Disease (COPD), Cystic Fibrosis and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 67: Germany 15-Year Perspective for Pulmonary /
Respiratory Drug Delivery by Application - Percentage Breakdown
of Value Sales for Asthma, Chronic Obstructive Pulmonary
Disease (COPD), Cystic Fibrosis and Other Applications for the
Years 2012, 2021 & 2027

Table 68: Germany Recent Past, Current & Future Analysis for
Pulmonary / Respiratory Drug Delivery by Product - Metered Dose
Inhalers, Dry Powder Inhalers and Nebulizers - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 69: Germany Historic Review for Pulmonary / Respiratory
Drug Delivery by Product - Metered Dose Inhalers, Dry Powder
Inhalers and Nebulizers Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 70: Germany 15-Year Perspective for Pulmonary /
Respiratory Drug Delivery by Product - Percentage Breakdown of
Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and
Nebulizers for the Years 2012, 2021 & 2027

ITALY
Table 71: Italy Recent Past, Current & Future Analysis for
Pulmonary / Respiratory Drug Delivery by Application - Asthma,
Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis
and Other Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 72: Italy Historic Review for Pulmonary / Respiratory
Drug Delivery by Application - Asthma, Chronic Obstructive
Pulmonary Disease (COPD), Cystic Fibrosis and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 73: Italy 15-Year Perspective for Pulmonary / Respiratory
Drug Delivery by Application - Percentage Breakdown of Value
Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD),
Cystic Fibrosis and Other Applications for the Years 2012, 2021 &
2027

Table 74: Italy Recent Past, Current & Future Analysis for
Pulmonary / Respiratory Drug Delivery by Product - Metered Dose
Inhalers, Dry Powder Inhalers and Nebulizers - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 75: Italy Historic Review for Pulmonary / Respiratory
Drug Delivery by Product - Metered Dose Inhalers, Dry Powder
Inhalers and Nebulizers Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 76: Italy 15-Year Perspective for Pulmonary / Respiratory
Drug Delivery by Product - Percentage Breakdown of Value Sales
for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers
for the Years 2012, 2021 & 2027

UNITED KINGDOM
Pulmonary / Respiratory Drug Delivery Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in the United Kingdom
for 2022 (E)
Table 77: UK Recent Past, Current & Future Analysis for
Pulmonary / Respiratory Drug Delivery by Application - Asthma,
Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis
and Other Applications - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 78: UK Historic Review for Pulmonary / Respiratory Drug
Delivery by Application - Asthma, Chronic Obstructive Pulmonary
Disease (COPD), Cystic Fibrosis and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 79: UK 15-Year Perspective for Pulmonary / Respiratory
Drug Delivery by Application - Percentage Breakdown of Value
Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD),
Cystic Fibrosis and Other Applications for the Years 2012, 2021 &
2027

Table 80: UK Recent Past, Current & Future Analysis for
Pulmonary / Respiratory Drug Delivery by Product - Metered Dose
Inhalers, Dry Powder Inhalers and Nebulizers - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 81: UK Historic Review for Pulmonary / Respiratory Drug
Delivery by Product - Metered Dose Inhalers, Dry Powder
Inhalers and Nebulizers Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 82: UK 15-Year Perspective for Pulmonary / Respiratory
Drug Delivery by Product - Percentage Breakdown of Value Sales
for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers
for the Years 2012, 2021 & 2027

REST OF EUROPE
Table 83: Rest of Europe Recent Past, Current & Future Analysis
for Pulmonary / Respiratory Drug Delivery by Application -
Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic
Fibrosis and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 84: Rest of Europe Historic Review for Pulmonary /
Respiratory Drug Delivery by Application - Asthma, Chronic
Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 85: Rest of Europe 15-Year Perspective for Pulmonary /
Respiratory Drug Delivery by Application - Percentage Breakdown
of Value Sales for Asthma, Chronic Obstructive Pulmonary
Disease (COPD), Cystic Fibrosis and Other Applications for the
Years 2012, 2021 & 2027

Table 86: Rest of Europe Recent Past, Current & Future Analysis
for Pulmonary / Respiratory Drug Delivery by Product - Metered
Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 87: Rest of Europe Historic Review for Pulmonary /
Respiratory Drug Delivery by Product - Metered Dose Inhalers,
Dry Powder Inhalers and Nebulizers Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 88: Rest of Europe 15-Year Perspective for Pulmonary /
Respiratory Drug Delivery by Product - Percentage Breakdown of
Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and
Nebulizers for the Years 2012, 2021 & 2027

ASIA-PACIFIC
Pulmonary / Respiratory Drug Delivery Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Asia-Pacific for
2022 (E)
Table 89: Asia-Pacific Recent Past, Current & Future Analysis
for Pulmonary / Respiratory Drug Delivery by Application -
Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic
Fibrosis and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 90: Asia-Pacific Historic Review for Pulmonary /
Respiratory Drug Delivery by Application - Asthma, Chronic
Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 91: Asia-Pacific 15-Year Perspective for Pulmonary /
Respiratory Drug Delivery by Application - Percentage Breakdown
of Value Sales for Asthma, Chronic Obstructive Pulmonary
Disease (COPD), Cystic Fibrosis and Other Applications for the
Years 2012, 2021 & 2027

Table 92: Asia-Pacific Recent Past, Current & Future Analysis
for Pulmonary / Respiratory Drug Delivery by Product - Metered
Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 93: Asia-Pacific Historic Review for Pulmonary /
Respiratory Drug Delivery by Product - Metered Dose Inhalers,
Dry Powder Inhalers and Nebulizers Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 94: Asia-Pacific 15-Year Perspective for Pulmonary /
Respiratory Drug Delivery by Product - Percentage Breakdown of
Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and
Nebulizers for the Years 2012, 2021 & 2027

REST OF WORLD
Table 95: Rest of World Recent Past, Current & Future Analysis
for Pulmonary / Respiratory Drug Delivery by Application -
Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic
Fibrosis and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 96: Rest of World Historic Review for Pulmonary /
Respiratory Drug Delivery by Application - Asthma, Chronic
Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 97: Rest of World 15-Year Perspective for Pulmonary /
Respiratory Drug Delivery by Application - Percentage Breakdown
of Value Sales for Asthma, Chronic Obstructive Pulmonary
Disease (COPD), Cystic Fibrosis and Other Applications for the
Years 2012, 2021 & 2027

Table 98: Rest of World Recent Past, Current & Future Analysis
for Pulmonary / Respiratory Drug Delivery by Product - Metered
Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 99: Rest of World Historic Review for Pulmonary /
Respiratory Drug Delivery by Product - Metered Dose Inhalers,
Dry Powder Inhalers and Nebulizers Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 100: Rest of World 15-Year Perspective for Pulmonary /
Respiratory Drug Delivery by Product - Percentage Breakdown of
Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and
Nebulizers for the Years 2012, 2021 & 2027

IV. COMPETITION
Read the full report: https://www.reportlinker.com/p06361181/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001